Policy paper

2024 voluntary scheme for branded medicines pricing, access and growth

An agreement between DHSC, NHS England and ABPI to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector.

• From: Department of Health and Social Care
• Published: 14 December 2023

This was published under the 2022 to 2024 Sunak Conservative government

Documents

2024 voluntary scheme for branded medicines pricing, access and growth

PDF, 1.45 MB, 97 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annexes to the 2024 voluntary scheme for branded medicines pricing, access and growth

PDF, 825 KB, 79 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex 5: scheme calculations

ODS, 34.7 KB

This file is in an OpenDocument format

Details

The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) is a voluntary agreement between the Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI).

The voluntary scheme aims to:

• promote better patient outcomes and a healthier population
• support UK economic growth
• contribute to a financially sustainable NHS

The voluntary scheme will come into force on 1 January 2024 and will be in place for 5 years until 31 December 2028.

Published 14 December 2023